Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

737.71
-19.0200-2.51%
Post-market: 739.001.29+0.17%19:59 EDT
Volume:492.13K
Turnover:365.50M
Market Cap:77.99B
PE:17.74
High:759.47
Open:756.65
Low:736.64
Close:756.73
52wk High:821.11
52wk Low:476.49
Shares:105.72M
Float Shares:103.30M
Volume Ratio:0.71
T/O Rate:0.48%
Dividend:3.61
Dividend Rate:0.49%
EPS(TTM):41.59
EPS(LYR):41.48
ROE:14.87%
ROA:5.91%
PB:2.50
PE(LYR):17.78

Loading ...

Regeneron Director Arthur F. Ryan Reports Disposal of Common Shares

Reuters
·
Mar 04

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 03

Regeneron Pharma Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Mar 03

RBC Raises Price Target on Regeneron Pharmaceuticals to $765 From $745, Keeps Sector Perform Rating

MT Newswires Live
·
Mar 02

Regeneron Pharmaceuticals Inc : RBC Raises Target Price to $765 From $745

THOMSON REUTERS
·
Mar 02

Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Feb 28

EMA committee backs EU approval of Regeneron and Sanofi’s Dupixent for chronic spontaneous urticaria in children 2-11

Reuters
·
Feb 27

Regeneron Pharmaceuticals Inc - Final Decision Expected in Coming Months

THOMSON REUTERS
·
Feb 27

Regeneron Pharmaceuticals Inc - Chmp Recommendation Covers Children Aged 2-11 With Moderate-to-Severe Csu

THOMSON REUTERS
·
Feb 27

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

GlobeNewswire
·
Feb 27

Ema's Chmp: Committee Recommended to Extend Use of Dupixent (Dupilumab), for Treatment of Chronic Spontaneous Urticaria in Children Aged 2 to 11 Yrs

THOMSON REUTERS
·
Feb 27

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

GlobeNewswire
·
Feb 27

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 26

Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Feb 25

Regeneron, Sanofi announce FDA approval of Dupixent for AFRS

TIPRANKS
·
Feb 24

FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis in patients aged 6 and older

Reuters
·
Feb 24

Sanofi - Phase 3 Study Shows Dupixent Reduces Nasal Signs and Symptoms

THOMSON REUTERS
·
Feb 24

Sanofi - Approval Expands Our Approved Indications in Sino-Nasal Diseases to NOW Include Afrs, Alongside Chronic Rhinosinusitis With Nasal Polyps

THOMSON REUTERS
·
Feb 24

Press Release: Sanofi and Regeneron’s Dupixent Approved in the US as the First and Only Medicine for Allergic Fungal Rhinosinusitis

THOMSON REUTERS
·
Feb 24

Regeneron Director Huda Y. Zoghbi Disposes of Common Shares

Reuters
·
Feb 24